CSPC Baike (Shandong) Biopharmaceutical Co. Ltd. has patented new polycyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of Alzheimer’s disease, obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD; MASLD).

Foresight Therapeutics (Hefei) Co. Ltd. has prepared and tested new cardiac myosin inhibitors reported to be useful for the treatment of hypertrophic cardiomyopathy.

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. has reported new monoamine oxidase-B (MAO-B) inhibitors potentially useful for the treatment of depression, stroke, hypertension, obesity, Alzheimer’s and Parkinson’s disease.

Work at Suzhou Genhouse Bio Co. Ltd. has led to the identification of Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Serine/threonine-protein kinase NEK7 inhibitors are described in a recent Beijing Primegene Therapeutics Co. Ltd. patent. They are reported to be useful for the treatment of gout, osteoarthritis, amyotrophic lateral sclerosis, multiple sclerosis, ulcerative colitis, Alzheimer’s, Parkinson’s disease and cancer.

Rutgers, The State University of New Jersey has disclosed new RNA polymerase (bacterial) inhibitors potentially useful for the treatment of bacterial infections.

DCB-USA LLC and the Development Center for Biotechnology have patented heterocycle compounds acting as fMet-Leu-Phe receptor (fMLP; FPR1) antagonists reported to be useful for the treatment of cancer, acute respiratory distress syndrome, asthma, arthritis, chronic obstructive pulmonary disease, lung injury, ischemia-reperfusion injury and septicemia.

Forx Therapeutics AG has discovered new bicyclo heteroaryl poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Idorsia Pharmaceuticals Ltd. has patented macrocyclic compounds acting as orexin OX2 receptor agonists reported to be useful for the treatment of obesity, pain, fatigue, inflammation, cognitive, sleep, eating and mood disorders.

Work at Genecode AS has led to the identification of sulfonamide or sulfone compounds acting as GFRα1-RET receptor complex activators potentially useful for the treatment of neurological disorders.